Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    Japan Tobacco Inc is developing JTT-130, an orally active microsomal triglyceride transfer protein inhibitor, for the potential treatment of hyperlipidemia. By August 2005, the compound was undergoing a phase II clinical trial in Japan, as well as a phase I trial in Europe.
    Original languageEnglish
    Pages (from-to)495-499
    JournalIDRUGS
    Volume9
    Issue number7
    Publication statusPublished - 2006

    Fingerprint Dive into the research topics of 'Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia'. Together they form a unique fingerprint.

    Cite this